ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
‒ Key primary and secondary endpoints were met demonstrating a robust impact on NASH ‒ ‒ Vonafexor was safe and well tolerated ‒ ‒ Vonafexor is the first FXR agonist showing improvement of renal function over 12w treatment ‒ ENYO Pharma (ENYO), a private clinic